These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35321309)

  • 1. Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment.
    Buck SAJ; Braal CL; Hofman MM; Oomen-de Hoop E; de Bruijn P; Ghobadi Moghaddam-Helmantel IM; Hussaarts KGAM; Vastbinder MB; van Rossum-Schornagel QC; van Schaik RHN; Jager A; Koolen SLW; Mathijssen RHJ
    Ther Adv Med Oncol; 2022; 14():17588359221081075. PubMed ID: 35321309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.
    Martinez de Dueñas E; Ochoa Aranda E; Blancas Lopez-Barajas I; Ferrer Magdalena T; Bandrés Moya F; Chicharro García LM; Gómez Capilla JA; Zafra Ceres M; de Haro T; Romero Llorens R; Ferrer Albiach C; Ferriols Lisart R; Chover Lara D; López Rodríguez A; Munárriz Ferrandis J; Olmos Antón S
    Breast; 2014 Aug; 23(4):400-6. PubMed ID: 24685597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
    Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
    BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.
    Opdam FL; Dezentje VO; den Hartigh J; Modak AS; Vree R; Batman E; Smorenburg CH; Nortier JW; Gelderblom H; Guchelaar HJ
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):593-601. PubMed ID: 23228987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
    Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
    J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
    Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
    Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling.
    Dickschen K; Eissing T; Mürdter T; Schwab M; Willmann S; Hempel G
    Springerplus; 2014; 3():285. PubMed ID: 24936398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen.
    Schroth W; Winter S; Mürdter T; Schaeffeler E; Eccles D; Eccles B; Chowbay B; Khor CC; Tfayli A; Zgheib NK; Eichelbaum M; Schwab M; Brauch H
    Front Pharmacol; 2017; 8():582. PubMed ID: 28955222
    [No Abstract]   [Full Text] [Related]  

  • 9. Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report.
    Henderson SL; Teft WA; Kim RB
    BMC Cancer; 2016 May; 16():304. PubMed ID: 27169677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
    Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
    BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.
    Madlensky L; Natarajan L; Tchu S; Pu M; Mortimer J; Flatt SW; Nikoloff DM; Hillman G; Fontecha MR; Lawrence HJ; Parker BA; Wu AH; Pierce JP
    Clin Pharmacol Ther; 2011 May; 89(5):718-25. PubMed ID: 21430657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
    Klopp-Schulze L; Joerger M; Wicha SG; Ter Heine R; Csajka C; Parra-Guillen ZP; Kloft C
    Clin Pharmacokinet; 2018 Feb; 57(2):229-242. PubMed ID: 28540639
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Ahmed JH; Makonnen E; Fotoohi A; Aseffa A; Howe R; Aklillu E
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31547390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen.
    Braal CL; Hussaarts KGAM; Seuren L; Oomen-de Hoop E; de Bruijn P; Buck SAJ; Bos MEMM; Thijs-Visser MF; Zuetenhorst HJM; Mathijssen-van Stein D; Vastbinder MB; van Leeuwen RWF; van Gelder T; Koolen SLW; Jager A; Mathijssen RHJ
    Breast Cancer Res Treat; 2020 Nov; 184(1):107-113. PubMed ID: 32803636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts.
    Gong IY; Teft WA; Ly J; Chen YH; Alicke B; Kim RB; Choo EF
    Breast Cancer Res Treat; 2013 May; 139(1):61-9. PubMed ID: 23605084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
    Helland T; Henne N; Bifulco E; Naume B; Borgen E; Kristensen VN; Kvaløy JT; Lash TL; Alnæs GIG; van Schaik RH; Janssen EAM; Hustad S; Lien EA; Mellgren G; Søiland H
    Breast Cancer Res; 2017 Nov; 19(1):125. PubMed ID: 29183390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity.
    Welzen ME; Dezentjé VO; van Schaik RH; Colbers AP; Guchelaar HJ; van Erp NP; den Hartigh J; Burger DM; van Laarhoven HW
    Ther Drug Monit; 2015 Aug; 37(4):501-7. PubMed ID: 26192892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of therapeutic drug monitoring of endoxifen in Egyptian premenopausal patients with breast cancer given tamoxifen adjuvant therapy: A pilot study.
    El Desoky ES; Taha AF; Mousa HS; Ibrahim A; Saleh MA; Abdelrady MA; Hareedy MS
    J Oncol Pharm Pract; 2023 Oct; 29(7):1673-1686. PubMed ID: 36567618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
    Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
    Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
    Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
    Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.